Medindia

X

Aperion Biologics' New Treatment Method Promotes Xenographic ACL Transplants

by Vishnuprasad on  September 11, 2015 at 7:55 PM Research News   - G J E 4
Aperion Biologics, a medical device company, has taken major steps towards making xenografts. Xenograft is a competitive alternative for use in the nearly one million Anterior Cruciate Ligament (ACL) surgeries performed globally every year.
Aperion Biologics' New Treatment Method Promotes Xenographic ACL Transplants
Aperion Biologics' New Treatment Method Promotes Xenographic ACL Transplants
Advertisement

The company developed a treatment method for porcine ACL tissue that will prevent the tissue from triggering a  rejection response, without disrupting its ligament structure and mechanical properties.

Advertisement
The Z-Process includes a sterilization wash and subsequent treatments that target the identified culprits of rejection.

The first treatment exposes the tissue to enzymes that will digest antigens with an α-galactosyl epitope, since, despite their abundance in non-primate mammals, primates have developed the antibodies to reject these antigens.

The other one exposes it to molecules that will bind to the ends of the surface carbohydrate chains of the tissue, making these chains "invisible" to immune system cells that would otherwise bind to them and identify them as foreign.

Once the xenograft tissue is implanted, it becomes the scaffold to aid in a patient's natural regeneration of the damaged ACL.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All